KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables: 2018-2025

Historic Receivables for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $60.9 million.

  • Twist Bioscience's Receivables rose 64.82% to $60.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year increase of 38.00%. This contributed to the annual value of $60.9 million for FY2025, which is 64.82% up from last year.
  • Per Twist Bioscience's latest filing, its Receivables stood at $60.9 million for FY2025, which was up 64.82% from $36.9 million recorded in FY2024.
  • Twist Bioscience's 5-year Receivables high stood at $60.9 million for FY2025, and its period low was $36.9 million during FY2024.
  • For the 3-year period, Twist Bioscience's Receivables averaged around $48.2 million, with its median value being $46.9 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first decreased by 21.22% in 2024, then spiked by 64.82% in 2025.
  • Twist Bioscience's Receivables (Yearly) stood at $43.7 million in 2022, then grew by 7.29% to $46.9 million in 2023, then decreased by 21.22% to $36.9 million in 2024, then soared by 64.82% to $60.9 million in 2025.